Full-Time

Executive Director

Global Medical Affairs, Virology

Posted on 7/7/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Develops and commercializes biopharmaceuticals

No salary listed

Senior, Expert

Uxbridge, UK

In Person

Category
Healthcare Administration & Support
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Marketing
Data Analysis
Requirements
  • Subject matter expertise in Virology, specifically HIV Treatment and Prevention
  • Excellent written, verbal, and interpersonal, relationship-building and negotiating communication skills
  • Excellent strategic and organizational skills with attention to detail and ability to meet timelines in a fast-paced environment
  • Excellent leadership and teamwork skills
  • Excellent analytical and problem-solving skills with a demonstrated ability to identify and understand complex issues and problems and identify and query key findings from study data and publications
  • Experience in developing effective abstracts, manuscripts, posters, and slides and presenting at scientific meetings
  • Must be fully cognizant and adhere to regulatory and legal requirements for implementation science and other Medical Affairs activities
  • Able to work with a level of autonomy and independence
Responsibilities
  • Deliver high-quality medical education presentations at Gilead-sponsored programs, supporting local medical affairs teams on scientific exchange
  • Serve as a scientific expert for the Virology teams, collaborating on core strategies focused on research, publication, education, scientific exchange, and content development
  • Partner with Medical Information to ensure the creation and maintenance of high-quality professional communications for healthcare professionals in response to unsolicited requests for product information
  • Maintain regular contact with community advocates, government, and policy officials, and KOLs to identify data gaps, track research, and inform scientific exchange plans
  • Provide medical and scientific leadership at key scientific meetings, supporting planning and execution
  • Collaborate with colleagues throughout Gilead Sciences’ organization, including Clinical Research, Public Affairs, Government Affairs, Regulatory Affairs, and Commercial & Marketing
  • Provide expert insights on the development of scientific communication plans and medical affairs materials for internal and external stakeholders
  • Train Gilead colleagues on healthcare landscapes, disease areas, and therapeutic interventions including Gilead medicines
  • Facilitate complex clinical topics at global advisory programs attended by international thought leaders
  • Ensure external insights and expert understanding is incorporated into the therapy area strategic planning process
  • Act as a key scientific reviewer for study concepts, abstracts, and manuscripts, including early data analysis
  • Chair Research Committees and voice expertise at Gilead’s Phase IV Research Review Committees for HIV Investigator-Sponsored and Collaborative Research
  • Collaborate with HEOR and RWE teams on health economics and outcomes research projects
  • Work with Medical Affairs colleagues worldwide to pull through scientific and healthcare policy communications and publications from research projects
  • Anticipate future industry trends and opportunities, identifying novel and timely solutions for issues encountered with clinical studies and the treatment landscape
Desired Qualifications
  • Extensive experience in clinical practice, research, and medical education
  • Solid experience in Medical Affairs and/or Clinical Research including Phase II, III, and/or IV studies preferred
  • Flexibility to travel extensively is required

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and manufacturing practices. The company's goal is to enhance health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's oncology navigation grant program enhances its reputation in cancer care.
  • The $11 billion investment is expected to create significant economic value and jobs.
  • Partnerships in innovative cancer treatments position Gilead at the forefront of oncology.

What critics are saying

  • Layoffs and halted expansion plans indicate potential operational challenges in biologics.
  • The $202 million settlement may impact Gilead's financial standing and reputation.
  • Intensifying competition from companies like Amgen pressures Gilead's market performance.

What makes Gilead Sciences unique

  • Gilead's partnership with Kymera focuses on novel cancer treatments using molecular glue degraders.
  • The company invests heavily in R&D, with a $11 billion U.S. investment plan.
  • Gilead's collaborations aim to improve patient outcomes and healthcare access globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

Plant Services
Jul 4th, 2025
Factory fallout: Manufacturing plant closures and layoffs from Intel, Hasbro, Johnsonville, and more

According to Fierce Biotech, Gilead Sciences, a pharmaceutical company, is laying off 36 employees as part of a strategic shift that ended plans to expand its biologics facility in Oceanside, California.

Pipeline Review
Jun 26th, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences and Kymera Therapeutics enter into exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders.

24-7 Press Release
Jun 26th, 2025
Gilead Sciences, Inc. proudly Supports Unite for HER's Metastatic Breast Cancer Sustainer Program

PHILADELPHIA, PA, June 26, 2025 /24-7PressRelease/ - Unite for HER (UFH) and Gilead Sciences have partnered to provide a new integrative care program free to Black, Hispanic, and underserved metastatic breast cancer patients in the United States.

BioPharma Dive
Jun 25th, 2025
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

Gilead and Kymera will develop a molecular glue degrader for breast cancer and other solid tumors.

PR Newswire
Jun 1st, 2025
The Academy Of Oncology Nurse Patient Navigators And Gilead Sciences Partner To Launch Oncology Navigation Grant Program

GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation and enhancing patient outcomes within the healthcare setting. This initiative is designed to support the creation, enhancement, and expansion of innovative tools that optimize efficiency and elevate the critical role of oncology navigators.Following the AONN+ call for grant submissions in April, healthcare leaders across the country responded with creative applications, software solution ideas and healthcare system improvements. AONN+ looks to announce the recipients of the award, valued up to $500,000, in June with project work to begin in the July time frame. The AONN+ grant application process and implementation support for awardees also included help from Amplity, AONN+'s association management partner and strategic collaborator."Through this funding mechanism, AONN+ and Gilead are committed to addressing persistent challenges in cancer care by empowering navigators to play a pivotal role in improving patient access to navigation services, removing barriers to cancer care, and supporting treatment adherence," says Candice Roth, MSN, RN, CENP, Executive Director, AONN+. "Navigator utilization continues to present significant opportunities for optimizing patient outcomes, and this program seeks to provide impactful solutions that directly tie proposed tools to measurable improvements in patient care.""As part of Gilead's Community Cancer Collective, we are proud to partner with AONN+ on this exciting initiative in support of the oncology community," said Darren Tayama, M.D., Vice President, US Medical Affairs, Oncology. "Together, AONN+ and Gilead are advancing the future of cancer care through innovative solutions in oncology navigation."About the Academy of Oncology Nurse & Patient Navigators , Inc

INACTIVE